Literature DB >> 20861833

Topical immunization strategies.

C Czerkinsky1, J Holmgren.   

Abstract

Research has yielded an abundance of vaccine candidates against mucosal infections, but only few mucosal vaccines have been registered for human use. Extensive research is being carried out to identify new and safe adjuvants for mucosal immunization, novel delivery systems, including live vectors and reporter molecules for tissue- and cell-specific targeting of vaccine antigens. If these candidates are to reach those in need, several lessons from clinical and field research carried out under resource-poor settings must be considered. These lessons include the need to develop new vaccines that can be administered topically onto the skin or to the mucosa, without needles or expensive delivery devices. Such topical vaccines must be able to protect all age groups at risk, be safe and effective in immunocompromised people, and be able to contain epidemics following complex emergencies. The anatomical compartmentalization of immune responses imposes constraints on the selection of topical route(s) of vaccine administration and on strategies for measuring these responses, especially in young infants. Thus, the selection of any particular route of immunization is critical when designing and formulating vaccines against organ-specific infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861833     DOI: 10.1038/mi.2010.55

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  33 in total

Review 1.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

2.  Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.

Authors:  François Dalençon
Journal:  Hum Vaccin Immunother       Date:  2013-08-12       Impact factor: 3.452

3.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

Review 4.  Gas-filled microbubbles: Novel mucosal antigen-delivery system for induction of anti-pathogen's immune responses in the gut.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Gut Microbes       Date:  2017-05-25

Review 5.  Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance.

Authors:  Fernando Baquero; Teresa M Coque; Fernando de la Cruz
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 6.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

Review 7.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

8.  Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.

Authors:  Magali Terme; Mevyn Nizard; Cécile Badoual; Federico Sandoval; Michel-Francis Bureau; Ludovic Freyburger; Olivier Clement; Elie Marcheteau; Alain Gey; Guillaume Fraisse; Cécilia Bouguin; Nathalie Merillon; Estelle Dransart; Thi Tran; Françoise Quintin-Colonna; Gwennhael Autret; Marine Thiebaud; Muhammad Suleman; Sabine Riffault; Tzyy-Choou Wu; Odile Launay; Claire Danel; Julien Taieb; Jennifer Richardson; Laurence Zitvogel; Wolf H Fridman; Ludger Johannes; Eric Tartour
Journal:  Sci Transl Med       Date:  2013-02-13       Impact factor: 17.956

9.  The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.

Authors:  Derek J Royer; Meghan M Carr; Hem R Gurung; William P Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2017-07-31       Impact factor: 5.422

10.  The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.

Authors:  Elizabeth B Norton; Louise B Lawson; Zaid Mahdi; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2012-04-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.